990 related articles for article (PubMed ID: 25087600)
1. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
Boulenger JP; Loft H; Olsen CK
Int Clin Psychopharmacol; 2014 May; 29(3):138-49. PubMed ID: 24257717
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response.
Papakostas GI; Nielsen RZ; Dragheim M; Tonnoir B
J Psychiatr Res; 2018 Jun; 101():72-79. PubMed ID: 29554497
[TBL] [Abstract][Full Text] [Related]
4. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
Wang G; Gislum M; Filippov G; Montgomery S
Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
[TBL] [Abstract][Full Text] [Related]
5. The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine.
François C; Nielsen R; Danchenko N; Williams V; Lançon C
Curr Med Res Opin; 2017 Jun; 33(6):1057-1066. PubMed ID: 28277865
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
Mahableshwarkar AR; Jacobsen PL; Chen Y; Serenko M; Trivedi MH
Psychopharmacology (Berl); 2015 Jun; 232(12):2061-70. PubMed ID: 25575488
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.
Fagiolini A; Florea I; Loft H; Christensen MC
J Affect Disord; 2021 Mar; 283():472-479. PubMed ID: 33516560
[TBL] [Abstract][Full Text] [Related]
10. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.
Nishimura A; Aritomi Y; Sasai K; Kitagawa T; Mahableshwarkar AR
Psychiatry Clin Neurosci; 2018 Feb; 72(2):64-72. PubMed ID: 28858412
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.
Yu YM; Gao KR; Yu H; Shen YF; Li HF
J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692
[TBL] [Abstract][Full Text] [Related]
13. Vortioxetine for depression in adults.
Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
[TBL] [Abstract][Full Text] [Related]
14. Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.
Adair M; Christensen MC; Florea I; Loft H; Fagiolini A
J Affect Disord; 2023 May; 328():345-354. PubMed ID: 36708956
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
Baldwin DS; Florea I; Jacobsen PL; Zhong W; Nomikos GG
J Affect Disord; 2016 Dec; 206():140-150. PubMed ID: 27474960
[TBL] [Abstract][Full Text] [Related]
16. [Vortioxetine in the treatment of major depression].
de Bartolomeis A; Fagiolini A; Maina G
Riv Psichiatr; 2016; 51(6):215-230. PubMed ID: 27996982
[TBL] [Abstract][Full Text] [Related]
17. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
Inoue T; Nishimura A; Sasai K; Kitagawa T
Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
[TBL] [Abstract][Full Text] [Related]
18. Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to SSRI Therapy: Results of the VIVRE Study.
McIntyre RS; Florea I; Pedersen MM; Christensen MC
J Clin Psychiatry; 2023 May; 84(4):. PubMed ID: 37227402
[No Abstract] [Full Text] [Related]
19. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
Nomikos GG; Tomori D; Zhong W; Affinito J; Palo W
CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]